VANDERSON GERALDO ROCHA

(Fonte: Lattes)
Índice h a partir de 2011
22
Lattes
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Clínica Médica, Faculdade de Medicina - Docente
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/31 - Laboratório de Genética e Hematologia Molecular, Hospital das Clínicas, Faculdade de Medicina - Líder

Filtros

Mostrar mais
Limpar filtros

Configurações

Revista / Livro: Biology of Blood and Marrow Transplantation ×

Resultados de Busca

Agora exibindo 1 - 10 de 13
  • conferenceObject
  • article 5 Citação(ões) na Scopus
    HLA-Matched Unrelated Donors for Patients with Sickle Cell Disease: Results of International Donor Searches
    (2020) TOZATTO-MAIO, Karina; TORRES, Margareth Afonso; DEGAIDE, Neifi Hassan Saloum; CARDOSO, Juliana Fernandes; VOLT, Fernanda; PINTO, Ana Cristina Silva; OLIVEIRA, Danielli; ELAYOUBI, Hanadi; KASHIMA, Simone; LOISEAU, Pascale; VEELKEN, Hendrik; FERSTER, Alina; CAPPELLI, Barbara; RODRIGUES, Evandra Strazza; SCIGLIUOLO, Graziana Maria; KENZEY, Chantal; RUGGERI, Annalisa; ROCHA, Vanderson; SIMOES, Belinda Pinto; TAMOUZA, Ryad; GLUCKMAN, Eliane
    Sickle cell disease (SCD) is the most common inherited hemoglobinopathy. Hematopoietic stem cell transplantation (HCT) is the sole curative therapy for SCD, but few patients will have a matched sibling donor. Patients with SCD are mostly of African origin and thus are less likely to find a matched unrelated donor in international registries. Using HaploStats, we estimated HLA haplotypes for 185 patients with SCD (116 from a Brazilian center and 69 from European Society for Blood and Marrow Transplantation [EBMT] centers) and classified the ethnic origin of haplotypes. Then we assessed the probability of finding an HLA-matched unrelated adult donor (MUD), considering loci A, B, and DRB1 (6/6), in international registries. Most haplotypes were African, but Brazilians showed a greater ethnic admixture than EBMT patients. Nevertheless, the chance of finding at least one 6/6 potential allelic donor was 47% for both groups. Most potential allelic donors were from the US National Marrow Donor Program registry and from the Brazilian REDOME donor registry. Although the probability of finding a donor is higher than previously reported, strategies are needed to improve ethnic diversity in registries. Moreover, predicting the likelihood of having an MUD might influence SCD management. (C) 2020 American Society for Transplantation and Cellular Therapy.
  • conferenceObject
    Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease in a Single Institution in Brazil. Reproducing Good Results with a Reduced Toxicity Regimen
    (2017) FERNANDES, Juliana Folloni; MANTOVANI, Luiz Fernando Alves Lima; VENANCIO, Angela Mandelli; DORNA, Mayra; PASTORINO, Antonio Carlos; VASCONCELOS, Dewton; NETO, Antonio Condino; MOURA, Ana Carla Augusto; COLLASSANTI, Maria Dulce; ZANICHELLI, Maria Aparecida; CARNEIRO-SAMPAIO, Magda; ROCHA, Vanderson G.; ODONE FILHO, Vicente
  • conferenceObject
    SWOT Analysis of a Tool for Data Management in Hematopoietic Stem Cell Transplantation
    (2020) OTUYAMA, Leonardo Jun; MORAES, Bruna Del Guerra de Carvalho; MARIANO, Livia; ROCHA, Vanderson
  • article 4 Citação(ões) na Scopus
    Identification and Characterization of Hematopoietic Stem Cell Transplant Candidates in a Sickle Cell Disease Cohort
    (2019) V, Miriam Flor-Park; KELLY, Shannon; PREISS, Liliana; CUSTER, Brian; CARNEIRO-PROIETTI, Anna B. F.; ARAUJO, Aderson S.; LOUREIRO, Paula; MAXIMO, Claudia; RODRIGUES, Daniela O. W.; MOTA, Rosimere A.; SABINO, Ester C.; ROCHA, Vanderson
    Sickle cell disease (SCD) is associated with significant morbidity, and allogeneic hematopoietic stem cell transplantation (HSCT) remains the primary curative treatment. Recently, the Brazilian Ministry of Health released a regulation that required the publically funded healthcare system to pay for HSCT for SCD patients with defined indications. We used an existing 2794-member SCD cohort established during 2013 to 2015 to characterize candidates for HSCT and estimate the number of possible donors. Of 2064 patients with SC anemia (SCA), 152 of 974 children (16%) and 279 of 1090 adults (26%) had at least 1 HSCT indication. The most common indication for transplant was stroke (n = 239) followed by avascular necrosis (n = 96), priapism (n = 82), cerebrovascular disease (n = 55), >2 vaso-occlusive episodes (n = 38), alloantibodies and chronic transfusion therapy (n = 18), and >2 acute chest syndrome episodes (n = 11). Increasing age, number of transfusions, abnormal transcranial Doppler, retinopathy, dactylitis, and use of hydroxyurea were more frequent in the 152 children with an indication for HSCT compared with 822 without (P < .001). Of 152 children and 279 adults meeting the eligibility definition, 77 (50%) and 204 (73%), respectively, had at least 1 non-SCD full sibling who could potentially serve as a donor. In conclusion, in a large cohort of SCA patients, 16% of children and 26% of adults had at least 1 indication for HSCT; these indications were associated with the severity of the disease. This study provides clinical data necessary for estimating the costs and infrastructure that would be required to implement HSCT in a public healthcare system. (C) 2019 American Society for Transplantation and Cellular Therapy.
  • conferenceObject
    Comparative Analysis of Conditioning Regimens in Patients Undergoing Autologous Hematopoietic STEM CELL Transplant for Lymphoma in a Single Brazilian Center
    (2019) SCHMIDT-FILHO, Jayr; RAYOL, Sergio; YAMAGUCHI, Marcela; ATANAZIO, Marcelo; MARIANO, Livia; ROSSETTI, Renata; ROCHA, Vanderson
  • article 13 Citação(ões) na Scopus
    Cord Blood Unit Dominance Analysis and Effect of the Winning Unit on Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee of Cellular Therapy, Immunobiology Working Party, and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
    (2018) TOZATTO-MAIO, Karina; GIANNOTTI, Federica; LABOPIN, Myriam; RUGGERI, Annalisa; VOLT, Fernanda; PAVIGLIANITI, Annalisa; KENZEY, Chantal; HAYASHI, Hiromi; CORNELISSEN, Jan; MICHALLET, Mauricette; KARAKASIS, Dimitrios; DECONINCK, Eric; ROHRLICH, Pierre-Simon; TOUR, Regis Peffault de la; BLAISE, Didier; PETERSEN, Eefke; D'AVENI, Maud; SENGELOEV, Henrik; LAMY, Thierry; RUSSELL, Nigel H.; FORCADE, Edouard; CRADDOCK, Charles F.; NAGLER, Arnon; GLUCKMAN, Eliane; ROCHA, Vanderson
    Usually, after double umbilical cord blood transplantation (DUCBT), only 1 of the transplanted units persists in the long term. The characteristics of the winning cord blood unit (W-CBU) that determine unit dominance and how they influence the outcomes of DUCBT remain unclear. We retrospectively analyzed 347 patients with acute leukemia transplanted with a DUCBT (694 CBU) from 2005 to 2013 who had documented neutrophil engraftment and a W-CBU identified by chimerism analysis, to identify unit characteristics impacting on dominance. Median age at DUCBT was 40 years and median follow-up was 35 months. Among W-CBUs, 41% were >= 5/6 HLA matched to the recipient and 59% were <= 4/6. Multivariate analysis indicated that <= 4/6 HLA-matched W-CBUs led to lower leukemia-free survival (44% versus 56%; hazard ratio [HR], 1.5; P= .032) and overall survival (49% versus 62%; HR, 1.5; P= .028), increased nonrelapse mortality (26% versus 18%; HR, 1.9; P= .027), and acute graft-versus-host disease (46% versus 35%; HR, 1.7; P= .013). We were unable to predict unit dominance, but we demonstrated that outcomes were strongly influenced by the degree of HLA mismatch between W-CBU and recipient. Therefore, selection of both units with the lower number of HLA mismatches with the recipient is indicated. (C) 2018 American Society for Blood and Marrow Transplantation.
  • article 2 Citação(ões) na Scopus
    Umbilical Cord Blood Cytomegalovirus Serostatus Does Not Have an Impact on Outcomes of Umbilical Cord Blood Transplantation for Acute Leukemia
    (2017) NIKOLAJEVA, Olga; ROCHA, Vanderson; DANBY, Robert; RUGGERI, Annalisa; VOLT, Fernanda; BAUDOUX, Etienne; GOMEZ, Susana G.; KOEGLER, Gezine; LARGHERO, Jerome; LECCHI, Lucilla; MARTINEZ, Mar Sanchez; NAVARRETE, Cristina; POUTHIERS, Fabienne; QUEROL, Sergio; KENZEY, Chantal; SZYDLO, Richard; GLUCKMAN, Eliane; MADRIGAL, Alejandro
    Several studies have reported an impact of adult hematopoietic stem cell donor cytomegalovirus (CMV) serostatus on allogeneic hematopoietic cell transplantation outcomes. Limited data, however, are available on the impact of cord blood unit (CBU) CMV serostatus on allogeneic umbilical cord blood transplantation (UCBT) outcomes. We analyzed, retrospectively, the impact of CBU CMV serostatus on relapse incidence (RI) and 2-year nonrelapse mortality (NRM) of single-unit CBU transplantation for acute leukemia. Data from 1177 de novo acute leukemia pediatric and adult patients transplanted within European Group for Blood and Marrow Transplantation centers between 2000 and 2012 were analyzed. CBUs were provided by the European Cord Blood Banks. The median follow-up time for live patients was 59.9 months. The recipients of CMV-seropositive and -seronegative CBUs showed a comparable RI (33% versus 35%, respectively, P=.6) and 2-year cumulative incidence of NRM (31% versus 32%, respectively, P =.5). We conclude that CBU CMV serostatus did not influence RI and NRM in de novo acute leukemia patients after allo-UCBT and should not be included as a criteria for cord blood choice. (C) 2017 American Society for Blood and Marrow Transplantation.
  • article 33 Citação(ões) na Scopus
    Outcomes after Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Patients with Primary Immunodeficiency Diseases
    (2020) FERNANDES, Juliana Folloni; NICHELE, Samantha; ARCURI, Leonardo Javier; RIBEIRO, Lisandro; ZAMPERLINI-NETTO, Gabriele; LOTH, Gisele; RODRIGUES, Ana Luiza Melo; KUWAHARA, Cilmara; KOLISKI, Adriana; TRENNEPOHL, Joanna; GARCIA, Julia Lopes; DAUDT, Liane Esteves; SEBER, Adriana; GOMES, Alessandra Araujo; FASTH, Anders; PASQUINI, Ricardo; HAMERSCHLAK, Nelson; ROCHA, Vanderson; BONFIM, Carmem
    Allogeneic hematopoietic stem cell transplantation (HCT) can cure primary immunodeficiency diseases (PID). When a HLA-matched donor is not available, a haploidentical family donor may be considered. The use of T cell-replete haploidentical HCT with post-transplantation cyclophosphamide (haplo-PTCy) in children with PID has been reported in few case series. A donor is usually readily available, and haplo-PTCy can be used in urgent cases. We studied the outcomes of 73 patients with PID who underwent haplo-PTCy, including 55 patients who did so as a first transplantation and 18 who did so as a salvage transplantation after graft failure of previous HCT. The median patient age was 1.6 years. Most of the children were male (n = 54) and had active infection at the time of transplantation (n = 50); 10 children had severe organ damage. The diagnosis was severe combined immunodeficiency (SCID) in 34 patients and non-SCID in 39 (Wiskott-Aldrich syndrome; n = 14; chronic granulomatous disease, n = 10; other PID, n = 15). The median duration of follow-up of survivors was 2 years. The cumulative incidence of neutrophil recovery was 88% in the SCID group and 84% in non-SCID group and was 81% for first transplantations and 83% after a salvage graft. At 100 days, the cumulative incidence of acute GVHD grade II-IV and III-IV was 33% and 14%, respectively. The majority of patients reached 200/mu L CD4(+) and 1000/mu L CD3(+) cell counts between 3 and 6 months. The estimated 2-year overall survival was 66%; it was 64% for SCID patients and 65% for non-SCID patients and 63% for first HCT and 77% for salvage transplantations. Twenty-five patients died, most of them due to infection early after transplantation (before 100 days). In conclusion, haplo-PTCy is a feasible procedure, can cure two-thirds of children with PID, and can be used as rescue treatment for previous graft failure. (C) 2020 American Society for Transplantation and Cellular Therapy.
  • article 24 Citação(ões) na Scopus
    Factors Associated with Long-Term Risk of Relapse after Unrelated Cord Blood Transplantation in Children with Acute Lymphoblastic Leukemia in Remission
    (2017) PAGE, Kristin M.; LABOPIN, Myriam; RUGGERI, Annalisa; MICHEL, Gerard; HEREDIA, Cristina Diaz de; O'BRIEN, Tracey; PICARDI, Alessandra; AYAS, Mouhab; BITTENCOURT, Henrique; VORA, Ajay J.; TROY, Jesse; BONFIM, Carmen; VOLT, Fernanda; GLUCKMAN, Eliane; BADER, Peter; KURTZBERG, Joanne; ROCHA, Vanderson
    For pediatric patients with acute lymphoblastic leukemia (ALL), relapse is an important cause of treatment failure after unrelated cord blood transplant (UCBT). Compared with other donor sources, relapse is similar or even reduced after UCBT despite less graft-versus-host disease (GVHD). We performed a retrospective analysis to identify risk factors associated with the 5-year cumulative incidence of relapse after UCBT. In this retrospective, registry-based study, we examined the outcomes of 640 children (<18 years) with ALL in first complete remission (CR1; n = 257, 40%) or second complete remission (CR2; n = 383, 60%) who received myeloablative conditioning followed by a single-unit UCBT from 2000 to 2012. Most received antithymocyte globulin (88%) or total body irradiation (TBI; 69%), and cord blood grafts were primarily mismatched at 1 (50%) or 2(+) (34%) HLA loci. Considering patients in CR1, the rates of 5-year overall survival (OS), leukemia-free survival (LFS), and relapse were 59%, 52%, and 23%, respectively. In multivariate analysis (MVA), acute GVHD (grades II to IV) and TBI protected against relapse. In patients in CR2, rates of 5-year OS, LFS, and the cumulative incidence of relapse were 46%, 44%, and 28%, respectively. In MVA, longer duration from diagnosis to UCBT >= 30 months) and TBI were associated with decreased relapse risk. Importantly, receiving a fully HLA matched graft was a strong risk factor for increased relapse in MVA. An exploratory analysis of all 640 patients supported the important association between the presence of acute GVHD and less relapse but also demonstrated an increased risk of nonrelapse mortality. In conclusion, the impact of GVHD as a graft-versus-leukemia marker is evident in pediatric ALL after UCBT. Strategies that promote graft-versus-leukemia while harnessing GVHD should be further investigated. (C) 2017 American Society for Blood and Marrow Transplantation.